Physician profile
John C Conroy
NPI 1770626269
$3,134.79
in general payments reported to CMS, 2019-2025
30 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2021: $48.62 · 2022: $199 · 2023: $271 · 2024: $755 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $431.42 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $302.71 | 2024-2025 | |
| Pfizer INC. | $267.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $251.65 | 2019-2025 | Eliquis |
| Amgen INC. | $219.60 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Lilly USA, LLC | $205.39 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $173.07 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $166.07 | 2019-2025 | Rybelsus, Ozempic |
| Lightforce Orthodontics, INC. | $141.60 | 2024 | |
| Janssen Pharmaceuticals, INC | $137.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $136.69 | 2019 | |
| Merck Sharp & Dohme LLC | $125.70 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $97.54 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Allergan, INC. | $55.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.97 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.32 | 2019 | |
| Ironwood Pharmaceuticals, INC | $31.06 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $28.75 | 2025 | Neffy |
| Dexcom, INC. | $25.29 | 2024 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $24.71 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.08 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $22.91 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.37 | 2019 | |
| Mylan Specialty L.P. | $17.59 | 2019 | |
| Horizon Therapeutics Plc | $16.71 | 2019 | |
| Electromed, INC. | $15.89 | 2019 | |
| Astellas Pharma US INC | $12.90 | 2019 | |
| Assertio Therapeutics, INC. | $12.67 | 2019 | |
| Eisai INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Conroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.